Johnson & Johnson (NYSE:JNJ) Stock Position Increased by Eubel Brady & Suttman Asset Management Inc.

Eubel Brady & Suttman Asset Management Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 130,279 shares of the company’s stock after buying an additional 3,364 shares during the period. Johnson & Johnson accounts for approximately 4.4% of Eubel Brady & Suttman Asset Management Inc.’s portfolio, making the stock its 6th largest holding. Eubel Brady & Suttman Asset Management Inc.’s holdings in Johnson & Johnson were worth $22,287,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Marathon Capital Management lifted its stake in shares of Johnson & Johnson by 4.6% during the third quarter. Marathon Capital Management now owns 27,264 shares of the company’s stock valued at $4,404,000 after buying an additional 1,200 shares during the period. Castle Rock Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 3.9% during the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock valued at $2,119,000 after buying an additional 479 shares during the period. Blueshift Asset Management LLC lifted its stake in shares of Johnson & Johnson by 671.9% during the third quarter. Blueshift Asset Management LLC now owns 30,365 shares of the company’s stock valued at $4,904,000 after buying an additional 26,431 shares during the period. Pallas Capital Advisors LLC raised its stake in Johnson & Johnson by 42.1% during the third quarter. Pallas Capital Advisors LLC now owns 68,839 shares of the company’s stock worth $11,363,000 after purchasing an additional 20,404 shares during the period. Finally, Achmea Investment Management B.V. raised its stake in Johnson & Johnson by 1.6% during the third quarter. Achmea Investment Management B.V. now owns 240,368 shares of the company’s stock worth $38,819,000 after purchasing an additional 3,829 shares during the period. 68.78% of the stock is currently owned by institutional investors and hedge funds.

JNJ traded down $1.02 during trading hours on Friday, reaching $176.85. 7,704,405 shares of the stock traded hands, compared to its average volume of 7,967,943. The firm’s fifty day simple moving average is $177.83 and its two-hundred day simple moving average is $170.32. The company has a market cap of $465.36 billion, a price-to-earnings ratio of 23.97, a PEG ratio of 2.92 and a beta of 0.66. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The business had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period last year, the business earned $2.59 EPS. On average, research analysts predict that Johnson & Johnson will post 10.2 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be issued a dividend of $1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.56%. The ex-dividend date is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.14%.

In other news, VP Thibaut Mongon sold 23,681 shares of the firm’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider William Hait sold 29,699 shares of the firm’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares in the company, valued at $14,729,724.88. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.

A number of equities analysts have weighed in on JNJ shares. Raymond James increased their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 30th. Finally, Bank of America initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $188.57.

About Johnson & Johnson (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.